DMC's Project for Ginkgo Bioworks Featured on 60 Minutes
Ginkgo Bioworks, a biotech company that DMC recently partnered with was featured on the February 28, 2021 episode of 60 Minutes. Ginkgo co-founder and CEO Jason Kelly discussed their efforts to optimize the manufacturing process for RNA.
Optimizing Bioengineering
Ginkgo Bioworks processes tens of thousands of coronavirus tests daily from their 18,000-square-foot facility in Boston. In his interview with 60 Minutes, Kelly shared that their efforts to bioengineer bacteria to produce DNA and enzymes that are needed to create RNA for the COVID vaccine resulted in triple the amount of these key ingredients. Kelly is optimistic that by changing the DNA of the bacteria, Ginkgo can achieve results of 10X or 50X.
DMC's Contribution
DMC is proud to support Ginkgo in this critical effort to improve COVID testing and research. We provided Ginkgo with a comprehensive automation system for their new mass test processing lab.
DMC engineer Corey Zheng speaks with Ginkgo Bioworks CEO Jason Kelly
In need of an update to their mostly manual existing system, Ginkgo reached out to DMC to develop and implement an automated testing solution to meet the growing demand for COVID testing. DMC leveraged our MagneMotion experience and implemented all application development, SCADA, and PLC solutions for the turnkey system.
Keep an eye out for DMC engineers John Michael Frullo and Corey Zheng in the 60 Minutes clip!
DMC engineer John Michael Frullo speaks with Ginkgo Bioworks CEO Jason Kelly
Learn more about DMC's manufacturing automation expertise.
Comments
There are currently no comments, be the first to post one.